BR112019007954A2 - inibidor da aldosterona sintase - Google Patents
inibidor da aldosterona sintaseInfo
- Publication number
- BR112019007954A2 BR112019007954A2 BR112019007954A BR112019007954A BR112019007954A2 BR 112019007954 A2 BR112019007954 A2 BR 112019007954A2 BR 112019007954 A BR112019007954 A BR 112019007954A BR 112019007954 A BR112019007954 A BR 112019007954A BR 112019007954 A2 BR112019007954 A2 BR 112019007954A2
- Authority
- BR
- Brazil
- Prior art keywords
- tetrahydroimidazo
- cyanophenyl
- disorders
- pyridine
- relates
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- CLPFFLWZZBQMAO-CQSZACIVSA-N 4-[(5r)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-CQSZACIVSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- QPMXWEHWAGTWOC-PFEQFJNWSA-N P(=O)(O)(O)O.C(#N)C1=CC=C(C=C1)[C@H]1CCCC=2N1C=NC2 Chemical compound P(=O)(O)(O)O.C(#N)C1=CC=C(C=C1)[C@H]1CCCC=2N1C=NC2 QPMXWEHWAGTWOC-PFEQFJNWSA-N 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
a presente invenção refere-se a um composto selecionado de (r)-(+)-5-(p-cianofenil)-5,6,7,8-tetra-hidroimidazo[1,5-a]piridina e um sal farmaceuticamente aceitável do mesmo e em particular ao sal fosfato de (r)-(+)-5-(p-cianofenil)-5,6,7,8-tetra-hidroimidazo[1,5-a]piridina, ambos tendo de preferência um excesso enantiomérico da forma (r) maior do que ou igual a 97%. além disso, a presente invenção refere-se às composições farmacêuticas compreendendo as mesmas, seu uso como um medicamento e métodos de tratamento de doenças e distúrbios em seres humanos, incluindo mulheres em idade fértil e pacientes pediátricos em que a sobre-exposição à aldosterona contribui para os efeitos prejudiciais dos referidos distúrbios e doenças, bem como processos para preparar os referidos compostos inventivos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413635P | 2016-10-27 | 2016-10-27 | |
| EP16205019 | 2016-12-19 | ||
| PCT/EP2017/077511 WO2018078049A1 (en) | 2016-10-27 | 2017-10-26 | Aldosterone synthase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019007954A2 true BR112019007954A2 (pt) | 2019-07-02 |
Family
ID=60162205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019007954A BR112019007954A2 (pt) | 2016-10-27 | 2017-10-26 | inibidor da aldosterona sintase |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10822332B2 (pt) |
| EP (1) | EP3532056A1 (pt) |
| JP (2) | JP7130636B2 (pt) |
| KR (2) | KR102506380B1 (pt) |
| CN (2) | CN109890389B (pt) |
| AU (2) | AU2017350484B2 (pt) |
| BR (1) | BR112019007954A2 (pt) |
| CA (1) | CA3040803A1 (pt) |
| CL (1) | CL2019001131A1 (pt) |
| IL (2) | IL301471A (pt) |
| MX (2) | MX2019004937A (pt) |
| SG (1) | SG11201903803UA (pt) |
| ZA (1) | ZA201903149B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3532056A1 (en) * | 2016-10-27 | 2019-09-04 | Damian Pharma AG | Aldosterone synthase inhibitor |
| US11992479B2 (en) | 2018-05-03 | 2024-05-28 | Damian Pharma Ag | R-fadrozole for use in the treatment of aldostonerism |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5428160A (en) * | 1982-12-21 | 1995-06-27 | Ciba-Geigy Corporation | Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives |
| MTP1076B (en) | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| EP1282410A2 (en) | 2000-04-12 | 2003-02-12 | Novartis AG | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1842543A1 (en) * | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| SI2804863T1 (sl) * | 2012-01-17 | 2016-05-31 | Novartis Ag | Nove oblike in soli zaviralca sinteze ali aromataze dihidropropirolo(1,2-c)imidazolil aldosterona |
| EP3532056A1 (en) * | 2016-10-27 | 2019-09-04 | Damian Pharma AG | Aldosterone synthase inhibitor |
-
2017
- 2017-10-26 EP EP17787936.8A patent/EP3532056A1/en active Pending
- 2017-10-26 BR BR112019007954A patent/BR112019007954A2/pt unknown
- 2017-10-26 CA CA3040803A patent/CA3040803A1/en active Pending
- 2017-10-26 CN CN201780065333.4A patent/CN109890389B/zh active Active
- 2017-10-26 KR KR1020197011358A patent/KR102506380B1/ko active IP Right Grant
- 2017-10-26 AU AU2017350484A patent/AU2017350484B2/en active Active
- 2017-10-26 MX MX2019004937A patent/MX2019004937A/es unknown
- 2017-10-26 US US16/345,209 patent/US10822332B2/en active Active
- 2017-10-26 CN CN202210638632.5A patent/CN114853755A/zh active Pending
- 2017-10-26 JP JP2019522665A patent/JP7130636B2/ja active Active
- 2017-10-26 IL IL301471A patent/IL301471A/en unknown
- 2017-10-26 SG SG11201903803UA patent/SG11201903803UA/en unknown
- 2017-10-26 KR KR1020237007198A patent/KR20230037680A/ko not_active Application Discontinuation
-
2019
- 2019-04-16 IL IL266056A patent/IL266056B2/en unknown
- 2019-04-25 CL CL2019001131A patent/CL2019001131A1/es unknown
- 2019-04-26 MX MX2022006934A patent/MX2022006934A/es unknown
- 2019-05-20 ZA ZA2019/03149A patent/ZA201903149B/en unknown
-
2020
- 2020-08-12 US US16/991,856 patent/US11447491B2/en active Active
-
2022
- 2022-03-01 AU AU2022201401A patent/AU2022201401B2/en active Active
- 2022-08-09 US US17/883,732 patent/US20230047158A1/en active Pending
- 2022-08-24 JP JP2022133021A patent/JP2022176994A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022176994A (ja) | 2022-11-30 |
| JP2019532975A (ja) | 2019-11-14 |
| AU2017350484A1 (en) | 2019-05-23 |
| CN109890389B (zh) | 2022-07-01 |
| ZA201903149B (en) | 2020-02-26 |
| IL266056A (en) | 2019-06-30 |
| SG11201903803UA (en) | 2019-05-30 |
| IL266056B2 (en) | 2023-08-01 |
| MX2022006934A (es) | 2022-07-11 |
| US20210024519A1 (en) | 2021-01-28 |
| AU2022201401A1 (en) | 2022-03-24 |
| KR102506380B1 (ko) | 2023-03-03 |
| AU2022201401B2 (en) | 2024-02-15 |
| CN114853755A (zh) | 2022-08-05 |
| AU2017350484B2 (en) | 2021-12-02 |
| CA3040803A1 (en) | 2018-05-03 |
| KR20190071715A (ko) | 2019-06-24 |
| CL2019001131A1 (es) | 2019-09-06 |
| EP3532056A1 (en) | 2019-09-04 |
| US10822332B2 (en) | 2020-11-03 |
| CN109890389A (zh) | 2019-06-14 |
| US11447491B2 (en) | 2022-09-20 |
| IL301471A (en) | 2023-05-01 |
| US20190292180A1 (en) | 2019-09-26 |
| US20230047158A1 (en) | 2023-02-16 |
| KR20230037680A (ko) | 2023-03-16 |
| JP7130636B2 (ja) | 2022-09-05 |
| MX2019004937A (es) | 2019-06-24 |
| IL266056B1 (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| CO2017011038A2 (es) | Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca” | |
| BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| EA201790122A1 (ru) | Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение | |
| BR112017009276A8 (pt) | Pirazolo[1,5-a]pirimidinas substituídas e seu uso no tratamento de distúrbios médicos | |
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| BR112019003557A2 (pt) | derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos | |
| BR112018072552A8 (pt) | Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos | |
| BR112017016487A2 (pt) | 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia | |
| BR112014029851A2 (pt) | composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| BR112018070586A8 (pt) | Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos | |
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
| BR112017020818A2 (pt) | composto, uso de um composto, método, e, medicamento | |
| BR112019007954A2 (pt) | inibidor da aldosterona sintase | |
| HRP20210012T1 (hr) | Lijek za liječenje infekcija dijabetičkog stopala |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |